{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '6.1.2 Clinical Procedures/Assessments', '6.1.2.1 Adverse Event (AE) Monitoring', 'The investigator or qualified designee will assess each participant to evaluate for potential new', 'or worsening AEs as specified in the Schedule of Activities (Section 2.3) and more frequently', 'if clinically indicated. Adverse experiences will be graded and recorded throughout the study', 'and during the follow-up period according to NCI CTCAE Version 5.0 (see Appendix 2:', 'Common Terminology Criteria for Adverse Events V5.0 (CTCAE). Toxicities will be', 'characterized in terms regarding seriousness, causality, toxicity grading and action taken with', 'regard to study intervention.', 'Please refer to Section 6.2 for detailed information regarding the assessment and recording of', 'AEs.', '6.1.2.2 Full Physical Exam', 'The Investigator or qualified designee will perform a complete physical exam during the', 'screening period (both arms). Clinically significant abnormal findings should be recorded as', 'medical history. An additional full physical exam should be performed at the end of trial', 'intervention (Arm A). After the first dose of study treatment new clinically significant abnormal', 'findings should be recorded as AEs.', 'Investigators should pay attention to clinical signs related to previous serious illnesses.', '6.1.2.3 Directed Physical Exam', 'A directed physical exam should be performed at Day 1 Cycle 1 (Arm A). During the course of', 'active treatment, the Investigator or qualified designee will perform a directed physical exam', 'as clinically indicated and according to site specific routine. After the first dose of study', 'intervention, new clinically significant abnormal findings should be recorded as AEs.', 'Investigators should pay attention to clinical signs related to previous serious illnesses.', '6.1.2.4 Vital Signs', 'The Investigator or qualified designee will take vital signs at screening for patients of both', 'arms. In addition, for patients in Arm A prior to the administration of study treatment (Day 1', 'Cycle 1) and at the end of trial intervention. During the course of active treatment, the', 'Investigator or qualified designee will take vital signs as clinically indicated and according to', 'site specific routine and will record abnormal findings only if clinically significant. Vital signs', 'should include temperature, pulse, weight and blood pressure. Height will be measured at', 'screening only.', '6.1.2.5 12-Lead Electrocardiogram', 'A standard 12-lead electrocardiogram (ECG) will be performed at screening (both Arms). For', 'Arm A, ECG should be repeated prior to the first administration if screening ECG is older than', 'Confidential', 'Page 44 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '8 weeks, at least once during treatment at cycle 7 and at discontinuation of trial intervention', 'and whenever clinically indicated using local standard procedures. Clinically significant', 'abnormal findings from screening visit should be recorded as medical history, clinically', 'significant abnormal findings during treatment should be recorded as adverse event.', '6.1.2.6 Eastern Cooperative Oncology Group (ECOG) Performance Scale', 'The Investigator or qualified designee will assess the ECOG status (see Appendix 1) at', 'screening and every three months thereafter for the first 2 years after randomization.', '6.1.2.7 Tumor Imaging and Assessment of Disease', 'Tumor imaging is recommended to be acquired by computed tomography (CT). Magnetic', 'resonance imaging (MRI) may be alternatively used when CT with iodinated contrast is', 'contraindicated, when local practice mandates it or if clinically appropriate. It is recommended', 'to use the same imaging technique regarding modality, and the use of contrast should be used', 'in a participant throughout the study to optimize the reproducibility of the assessment of', 'existing and new tumor burden and improve the accuracy of the assessment. Imaging should', 'include the chest, abdomen, and pelvis at baseline to ensure absence of disease and it is', 'recommended to continue with this assessment for all subsequent imaging time points.', 'Participant baseline and follow-up imaging will be determined using local assessment', '(Investigator assessment), which in case of this trial is equal to evidence of new (previously', 'untreated) lesions during study conduct. In addition, images (including via other modalities)', 'that are obtained at an unscheduled time point to determine disease progression, as well as', 'imaging obtained for other reasons, but which demonstrate radiologic progression, should also', 'be used to determine progression.', '6.1.2.7.1 Initial Tumor Imaging', 'Initial tumor imaging at Screening will only be performed if last available tumor imaging is older', 'than 10 weeks. The study team must review screening images to confirm the participant has', 'no clinical or radiological evidence of disease (if images were obtained after treatment of', 'metastatic disease) or all known lesions have been treated in the meantime.', 'Tumor imaging performed as part of routine clinical management is acceptable for use as', 'screening tumor imaging if they cover thorax and abdomen and not older than 10 weeks prior', 'to the start of study intervention.', 'Tumor imaging prior to the definite treatment of colorectal cancer metastases as well as follow-', 'up images should be (additionally if applicable) provided for centrally assessing the local', 'control of lesions according to ablative technique (surgery VS. ablation VS. radiation).', 'Confidential', 'Page 45 of 79']\n\n###\n\n", "completion": "END"}